by IR Team | Feb 3, 2021 | News
AXIM Biotechnologies (OTCQB:AXIM) announces the start of clinical trials for ImmunoPass, the company’s rapid point-of-care test that semi-quantitatively measures levels of neutralizing antibodies to COVID-19. Measuring neutralizing antibodies in people after...
by IR Team | Jan 28, 2021 | News
IPM spoke with AXIM Biotech CEO John Huemoeller to see how his firm are going about seeking patent protection for its Covid-19 tests. Obtaining IP rights protections for Covid-19 related treatments and tests is the number one public health priority right now.The race...
by IR Team | Dec 15, 2020 | News
In what U.S. FDA commissioner Stephen Hahn billed as “a major milestone” in testing for the COVID-19 pandemic, the FDA has granted an emergency use authorization (EUA) to Ellume Ltd., of East Brisbane, Australia, for the company’s COVID-19 home test. The rapid...
by IR Team | Dec 15, 2020 | News
AXIM Biotechnologies (OTCQB:AXIM -2.4%) has filed an amended Emergency Use Authorization (EUA) application with the FDA. AXIM first filed the EUA in September for measuring COVID-19 neutralizing antibodies in plasma and serum through its rapid diagnostic test. The...
by IR Team | Dec 4, 2020 | News
A new enzyme-linked immunosorbent assay (ELISA)-based COVID-19 diagnostic test detects and ranks SARS-CoV-2 neutralizing antibodies by their potency in a simple and relatively short test time. The test developed internally by AXIM Biotechnologies, Inc. (San Diego, CA,...
by IR Team | Dec 4, 2020 | News
Intrivo Diagnostics announced that it has entered into a national distribution agreement with Concordance Healthcare Solutions and NDC to start the distribution and commercialisation of New Jersey-based Access Bio’s CareStart™ line of coronavirus testing products...
